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Abstract
Aiming to assess the association between measures of obesity and outcomes in coronary artery 
disease (CAD) patients. We included consecutive patients referred to cardiac rehabilitation 
because of prior CAD events, who were classified using BMI groups and sex-specific tertiles of 
waist-to-hip ratio (WHR). Follow-up was ascertained using a population-based, record linkage 
system that consists of complete data on all residents. A major cardiovascular event (MACE) was 
defined as the composite outcome including acute coronary syndromes, coronary 
revascularization, ventricular arrhythmias, stroke or death from any cause. The association 
between obesity measures and MACE was assessed using cox proportional hazards models 
adjusted for potential confounders. The cohort included 1529 patients (74% men) mean age ± SD 
63.1±12.5 years, 40% were obese by BMI. Eighty-eight percent of men and 57% of women were 
classified as having central obesity by WHR. Median follow-up was 5.7 years and 415 patients 
had a MACE event. After adjustment, a high WHR tertile was a significant predictor for MACE in 
women (HR=1.85 [95% Cl: 1.16, 2.94]; p=0.01), but not in men (HR=0.92 [95%CI: 0.69, 1.22]; 
p=0.54). This relationship in women persisted after further adjustment for BMI (HR=1.75 
[95%CI: 1.07, 2.87]; p=0.03). Obesity by BMI was not associated with MACE in either men 
(HR=1.07 [95%CI: 0.76, 1.51]; p=0.69) or women (HR=0.98 [95%CI: 0.62, 1.56]; p=0.95). In 
conclusion WHR is associated with a higher risk of MACE among women with CAD but not in 
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men. There was no obesity paradox when assessing obesity by BMI and MACE in CAD patients 
when including non-fatal events.
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Obesity; Coronary artery disease; cardiac rehabilitation
Introduction
Assessing obesity with the body mass index (BMI) has limitations, not only because BMI 
does not perfectly correlate with body adiposity but also because BMI does not measure fat 
distribution. BMI has been paradoxically linked to lower total and cardiovascular mortality 
in patients with coronary artery disease (CAD)1 while measurements of central obesity such 
as waist circumference (WC) or waist-to-hip ratio (WHR) have shown conflictive results.2,3 
Most of the evidence testing the obesity paradox or linking central obesity and outcomes in 
CAD patients has used mortality as the outcome of interest, with scant research testing the 
association between measures of obesity and major adverse cardiovascular events (MACE) 
including non-fatal clinical outcomes. In the general population WC and WHR are indirect 
estimations of visceral adiposity which is linked to insulin resistance, dyslipidemia, and 
increased cardiovascular risk.4 It is reasonable to believe that those mechanisms will 
continue to be relevant in the presence of CAD. In this study we test the hypotheses that in 
CAD patients, central obesity would be associated with increased MACE while obesity by 
BMI would either have none or paradoxical association with MACE.
Methods
We conducted a population-based, historical cohort study of all Olmsted County, Minnesota, 
residents over the age of 18 years that enrolled in phase II cardiac rehabilitation (CR) 
between the years 2002 and 2012 following a CAD event. Patients were identified using the 
resources of the Rochester Epidemiology Project (REP),5 a federally funded record linkage 
system that indexes medical records, medications, procedures, and other health related 
information from the primary providers of medical care in Olmsted County; Olmsted 
Medical Center, the Mayo Clinic and few other individual private providers. All tertiary 
care, cardiovascular procedures and CR occurred at Mayo Clinic during the study period. 
This serves as an ideal community-based infrastructure to investigate disease-associated risk 
factors and outcomes.5 The study protocol was reviewed and approved by the institutional 
review board of both the Mayo Clinic and Olmsted Medical Center. All included patients 
provided research authorization, as required by the state of Minnesota.
We identified patients referred for CR because of a myocardial infarction (MI) (ST or non-
ST-segment elevation MI), stable or unstable angina and coronary revascularization by either 
coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). We 
excluded patients on whom anthropometric measurements were not performed. Baseline 
information was collected electronically from the Rochester Epidemiology Project (REP) 
within 3 months of CR entry using the International Classification of Diseases-9th revision; 
this approach has been previously validated.6 Demographic and clinical characteristics, 
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laboratory values, blood pressure measurements and medications prescribed for the 
treatment of CAD were ascertained. For internal validation, a portion of this information was 
reviewed in duplicate by 2 investigators (J.M.I. and F.L.J.) who were masked to the baseline 
characteristics of patients.
Anthropometry at baseline was assessed during the CR entry evaluation according to the 
World Health Organization (WHO) Anthropometric Guidelines using structured protocols 
by trained nurses.7 Height without shoes was recorded to the nearest centimeter and weight 
was recorded to the nearest 0.1 kilogram using a stadiometer, BMI was calculated dividing 
weight in kilograms by height in meters squared. Hip circumference (HC) was measured at 
the widest portion of the buttocks with the tape horizontal in cm. WC was obtained at the 
midpoint between the lower margin of the lowest palpable rib and the top of the iliac crest in 
the mid-axillary line at the end of expiration. Measurements were performed standing. WHR 
was calculated by dividing WC by HC.
MACE included any of the following events: 1) any diagnosis of a new acute coronary 
syndrome, including both ST and non-ST-segment elevation myocardial infarction and 
unstable angina that required hospitalization; 2) coronary revascularization, including PCI 
and CABG; 3) stroke, including any non-traumatic brain hemorrhage or infarction; 4) 
ventricular arrhythmias warranting in-hospital management, and 6) death from any cause. 
Mortality information was obtained from the REP, which records vital status from federal 
and Minnesota state death registries. Each subject in the study sample was followed up from 
the date of cardiac rehabilitation entry (index date) until the occurrence of a first MACE 
event or date of last followup until December 1th 2014. All outcomes were passively 
followed through a review of the electronic medical records in the records-linkage system in 
duplicate by 2 physician investigators (J.M.I. and F.L.J.) who were blinded to baseline 
characteristics including WHR and BMI to assess inter-observer agreement. Consensus 
resolved all disagreements. We summarized baseline patient characteristics with frequencies 
and percentages, means ± standard deviations (SD), or medians and interquartile range 
(IQR), as appropriate. Patient characteristics were compared between men and women 
using, chi-square tests, fisher’s exact test or two-sample nonpaired t-tests, as appropriate. 
The Kappa (K) statistic was used to assess inter-observer agreement over comorbidities and 
also for each outcome composing MACE. BMI was analyzed both continuously and 
categorically using preestablished cutoffs.7 WHR was analyzed both continuously and 
categorically, using WHO criteria defining central obesity as WHR≥0.90 for men and 
WHR≥ 0.85 for women, and also using sex-adjusted tertiles due to differences in body 
composition by sex reported the literature demonstrating sex-specific outcomes when 
considering central obesity.8–10 The association between WHR and the time to first recorded 
MACE was assessed separately within men and women as a pre-specified analysis using 
Kaplan-Meier curves and Cox proportional hazards regression models. The models were 
adjusted for age, smoking, and history of heart failure, all known potential confounders in 
the association between obesity and Cardiovascular Disease (CVD) events. An additional 
model included BMI and an exploratory model adjusted for optimal medical therapy for 
CAD (defines as prescription of cardioprotective medication classes (statins, ACE inhibitors/
angiotensin II receptor blockers, β-blockers, and antiplatelet agents. The multiplicative 
interaction between BMI and WHR was also assessed as a separate term in our overall 
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model. We did not adjust for history of hypertension, diabetes or dyslipidemia because they 
are mechanistic factors linking obesity and CVD events, as generally accepted and 
recommended in obesity-related epidemiology. Findings were summarized using hazard 
ratios and 95% confidence intervals. The assumption of proportionality for the Cox 
proportional hazards models was assessed graphically and fulfilled. The functional form for 
WHR ratio (continuous) on the outcome was explored graphically with splines. Two-sided 
p-values less than 0.05 were considered statistically significant. All analyses were completed 
using JMP®, Version 12.1 and SAS® 9.4 (SAS Institute Inc., Cary, NC).
Results
Baseline patient characteristics are shown in Table 1. During a median follow-up of 5.7 
years (IQR: 3.5–8.8), 415 patients (73% men) had at least 1 MACE,representing 9,586 
person years, incidence of MACE was no different between sexes (p=0.10), as seen in Table 
2. Central obesity measured using WHR tertiles was associated with an increased risk of 
MACE in women whose 3 year event-free-survival rates were 90.0, 84.5, 77.4% (log rank 
p=0.01); but not in men, in whom event-free survival rates were 84.8, 82.0, and 85.0% (log 
rank p=0.10), as observed in Figure 1-A/B.
As seen in Table 3, multivariate modeling demonstrated that WHR tertile remained a 
significant predictor for MACE for women; The risk of MACE for women in the highest 
WHR tertile was almost two-fold higher when compared to those in the lowest tertile. This 
relationship did not change after further adjusting for BMI (HR=1.75 [95%CI: 1.07, 2.87]; 
p=0.03). For men, the adjusted risk of MACE for those in the highest WHR tertile was no 
different when compared to the lowest tertile, after adjusting for BMI (Adjusted HR=1.09, 
[95%CI: 0.79, 1.50] p=0.58). When assessing WHR as a continuous variable, a 0.10 increase 
in WHR was associated with a 32% increase in risk of MACE among women,but not among 
men, as seen in Table 3.This relationship remained constant after further adjusting for 
optimal medical therapy for CAD ( Data not shown). Obesity by BMI was not a significant 
predictor for MACE in either the whole cohort (HR 0.99, [95%CI: 0.76, 1.31] p=0.99) or in 
either men (HR=1.07 [95%CI: 0.76, 1.51]; p=0.69) or women (HR=0.98 [95%CI: 0.62, 
1.56]; p=0.95) when analyzed separately. This association remained constant when only 
considering waist circumference, as seen in Appendix 1.
Discussion
In this historical cohort study of patients with known CAD attending CR, we found that 
there is no obesity paradox when assessing the association between BMI and MACE, as 
seen for mortality.1 However, while WHR is not related to MACE in men, we observed that 
in women, a higher WHR was related to a higher risk of MACE, independent of BMI. Few 
studies have tested the association between obesity and MACE in CAD patients, while this 
is the first study to assess the risk of MACE when compared by WHR in patients with CAD.
Several studies have suggested that measures of central obesity, particularly WHR, provide 
incremental information beyond BMI, particularly in women.5,11–14 Cerhan et al.13 and 
Lassalle C et al.14 have shown the value of WC over BMI in prediction of total mortality 
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even with BMI units or categories, while Li et al.10 and Sahakyan et al.8 found that WHR 
relates to increased cardiovascular and mortality risk in women in all BMI categories. This 
was only seen in men with normal body weight.12 We found no significant association 
between central obesity and MACE in men; a finding that may be related to the high 
prevalence of central obesity in men, with only 12% with a normal WHR, so the statistical 
and discriminatory power to detect associations was limited (Unadjusted C-statistic, for 
Men=0.50 and for Women=0.60). These results are consistent with other cohorts where this 
relationship has also been considered modest.11,15 In the case of CAD patients undergoing 
cardiac rehabilitation, sex differences also appear to contribute additionally to the effect of 
obesity on clinical outcomes8,10,16. This relationship was demonstrated in a meta-analysis 
by Coutinho et al.9 that concluded that in patients with CAD with either normal or high 
BMI, measures of central obesity were directly associated with an increased mortality rates 
and that this association was significantly greater in women.
Our sex-specific differences in the relationship between WHR and MACE provide some 
insight into the effects that predict long-term outcomes, and expands on what we and other 
authors have found before.10,11,15,17,18 First, women are at higher risk in other populations, 
including post-myocardial infarction in-hospital mortality,19 incident CVD,10 total mortality 
in elderly patients,15,16 and CAD patients.9 These sex differences could be due to several 
physiologic, metabolic and hormonal differences between sexes. Second, fat and muscle 
distribution differs by sex. Men store more visceral fat20 while women with greater fat in 
pelvis and gluteo-femoral muscle 17,21 The distribution in women changes on the post-
menopausal state due to changes in steroid hormones, specifically estrogen.22,23 maintaining 
after this stage their pre-menopausal BMI concomitant with an increase in WC and decrease 
in HC leading to an increase in WHR.22 Third, those with enlarged abdominal adiposity may 
have an increased amount of androgen production and thus higher risk of CVD.23 Further 
studies are needed to confirm these hypotheses.
Importantly, we did not observe the “obesity paradox”, where individuals classified as 
overweight or obese by BMI have better survival than those with normal weight. Results that 
may be justified because of the inability of BMI to discriminate between fat mass and lean 
mass and so it leads to misclassification regarding CVD risk.11 Studies showing the obesity 
paradox have only included mortality as outcome.
This study has several strengths. The infrastructure of the REP provides excellent 
generalization to the US caucasian population in a community-based setting. Complete 
ascertainment of outcomes leads to minimization of loss to follow-up since they are applied 
to a relatively stable population,5 thereby reducing referral bias and increasing the 
generalizability of the results. Our blinded investigators independently verified 
comorbidities and outcomes improving the validity of our data. Our sex-stratified analysis 
evaluated the association of WHR and the composite endpoint of MACE, an important and 
widely used measure since it has a significant impact on medical decision making for 
cardiovascular patient care and treatment. MACE offers more information when it is 
included as an outcome, because it provides a better idea of safety, effectiveness of 
treatments, disability and reduction of quality of life, along with costs through the evaluation 
of non-fatal events, which has not been extensively studied. Lastly, our study had a 
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considerably longer follow-up compared to previous studies about prognosis of patients with 
CAD.9
This study is susceptible to a number of sources of bias. First, by limiting our sample 
exclusively to patients with CAD and measures of central obesity, we might introduce 
selection bias and limit the generalizability of our results . Second, our sample included 
mostly non-Hispanic white men, given the target population and the well-known lack of CR 
participation among women.24 Third, we could not account for additional confounders 
(genetic susceptibility, nutritional quality, physical activity, daily environment, sedentary 
behaviors, cardiorespiratory fitness, sleep disorders, duration of obesity, socio-economic 
status along with others).Fourth, because our estimates are based on a single measure of 
WHR as the exposure variable, assuming that it will not change through follow-up, 
misclassification bias could potentially affect our sample. Finally, subjects without central 
obesity who develop CAD do so as a result of other risk factors and therefore their risk for 
recurrent events would theoretically depend on the persistance of those non-obesity related 
factors. Although such sources of bias can limit causal inferences, the results of our study 
are still informative.
These results expand upon studies that have found a relationship between WHR and 
cardiovascular risk factors,25 metabolic syndrome,26 total and cardiovascular mortality,8,27 
and other CVD outcomes.18,27,28 Our study has potential implications for clinical care of 
individuals with CAD referred for CR. An early assessment of central adiposity in addition 
to BMI and application of lifestyle changes focused on caloric balance, healthy nutrition and 
tailored exercise prescription may have a positive impact on these patients as MACE events.
In conclusion, WHR was associated with a higher risk of MACE among women with CAD 
undergoing CR. Measuring WHR could be used as an additional measure to BMI for 
assessment of cardiovascular event risk in CAD patients with a higher impact among 
women.
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Appendix 1.: Adjusted Cox proportional hazard models testing the 
association between waist circumference tertiles and major adverse 
cardiovascular events among Men and Women.
Medina-lnojosa et al. Page 6
Am J Cardiol. Author manuscript; available in PMC 2019 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
M
en
(N
=8
07
)
W
o
m
en
(N
=3
09
)
M
od
el
 1
M
od
el
 2
M
od
el
 1
M
od
el
 2
M
ea
su
re
H
az
ar
d 
R
at
io
 (9
5%
CI
)
P 
Va
lu
e
C
-S
ta
tis
tic
H
az
ar
d 
R
at
io
 (9
5%
CI
)
P 
Va
lu
e
C
-S
ta
tis
tic
H
az
ar
d 
R
at
io
 (9
5%
CI
)
P 
Va
lu
e
C
-S
ta
tis
tic
H
az
ar
d 
R
at
io
 (9
5%
CI
)
P 
Va
lu
e
C
-S
ta
tis
tic
W
ai
st 
ci
rc
um
fe
re
nc
e 
se
x
-a
dju
ste
d 
te
rt
ile
s*
Lo
w
R
ef
er
en
t
R
ef
er
en
t
R
ef
er
en
t
R
ef
er
en
t
M
id
dl
e
1.
27
 (0
.89
,1.
83
)
0.
50
1.
24
 (0
.86
,1.
78
)
0.
61
1.
57
 (0
.79
, 3
.15
)
0.
61
1.
57
 (0
.78
,3.
17
)
0.
63
H
ig
h
1.
30
 (0
.91
, 1
.85
)
0.
25
1.
21
 (0
.84
, 1
.73
)
0.
40
3.
28
 (1
.75
,6.
36
)
0.
00
08
3.
42
 (1
.80
, 6
.74
)
0.
00
06
0.
50
0.
61
0.
61
0.
62
W
ai
st 
ci
rc
um
fe
re
nc
e 
co
n
tin
uo
us
, 
fo
r 1
 c
m
 
in
cr
ea
se
1.
00
 (0
.99
,1.
01
)
0.
16
1.
00
 (0
.99
, 1
.01
)
0.
26
1.
02
 (1
.01
,1.
04
)
0.
00
03
1.
02
 (1
.01
, 1
.03
)
0.
00
06
Cl
= 
co
nf
id
en
ce
 in
te
rv
al
M
od
el
 1
: A
dju
ste
d f
or 
ag
e, 
Mo
de
l 2
: A
dju
ste
d f
or 
Ag
e, 
sm
ok
ing
 an
d h
ist
ory
 of
 he
art
 fa
ilu
re
. (T
he
 va
ria
bl
e 
W
ai
st 
ci
rc
um
fe
re
nc
e 
w
as
 a
v
ai
la
bl
e 
in
 le
ss
 su
bje
cts
 th
an
 th
ose
 in
clu
de
d i
n t
ab
le 
3)
In
te
ra
ct
io
n 
be
tw
ee
n 
Bo
dy
 m
as
s i
nd
ex
 a
n
d 
w
ai
st 
ci
rc
um
fe
re
nc
e 
(in
 a 
mo
de
l w
ith
 B
od
y m
ass
 in
de
x
 a
n
d 
w
ai
st 
ci
rc
um
fe
re
nc
e),
 w
as
 n
o
t s
ta
tis
tic
al
ly
 si
gn
ifi
ca
nt
 (p
=>
0.0
5).
*
W
ai
st 
ci
rc
um
fe
re
nc
e 
se
x
-a
dju
ste
d t
ert
ile
s [
Me
n L
ow
: 
<
98
 cm
s (
N=
29
1 ,
M
AC
E=
64
), M
idd
le:
 98
 cm
s t
o <
10
8.5
6 c
ms
 (N
=2
47
, M
AC
E=
58
), H
igh
: ≥
10
8.5
6 c
ms
 (N
=2
69
, M
AC
E=
60
); 
W
o
m
en
 L
ow
: 
87
 c
m
s 
(N
=1
06
,M
AC
E=
19
), M
idd
le:
 87
 cm
s t
o <
10
1 c
ms
 (N
=1
00
,M
AC
E=
18
), H
igh
: ≥
10
1 c
ms
 (N
=1
03
,M
AC
E=
29
)j
Medina-lnojosa et al. Page 7
Am J Cardiol. Author manuscript; available in PMC 2019 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Reference
1Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F, 
Lopez-Jimenez F. Association of bodyweight with total mortality and with cardiovascular events in 
coronary artery disease: a systematic review of cohort studies The Lancet. 368:666–678.
2de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as 
predictors of cardiovascular events: meta-regression analysis of prospective studies European heart 
journal. 2007; 28:850–856. [PubMed: 17403720] 
3Seidell JC, Perusse L, Despres JP, Bouchard C. Waist and hip circumferences have independent and 
opposite effects on cardiovascular disease risk factors: the Quebec Family Study Am J Clin Nutr. 
2001; 74:315–321. [PubMed: 11522554] 
4Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Tokunaga K. Pathophysiology and pathogenesis 
of visceral fat obesity Annals of the New York Academy of Sciences. 1995; 748:399–406. 
[PubMed: 7695182] 
5St Sauver JL, Grossardt BR, Yawn BP, Melton LJ, Pankratz JJ, Brue SM, Rocca WA. Data Resource 
Profile: The Rochester Epidemiology Project (REP) medical records-linkage system International 
Journal of Epidemiology. 2012; 41:1614–1624. [PubMed: 23159830] 
6Chamberlain AM, St Sauver JL, Gerber Y, Manemann SM, Boyd CM, Dunlay SM, Rocca WA, 
Finney Rutten LJ, Jiang R, Weston SA, Roger VL. Multimorbidity in heart failure: a community 
perspective The American journal of medicine. 2015; 128:38–45. [PubMed: 25220613] 
7Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee., 
1995.
8Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, Coutinho T, 
Jensen MD, Roger VL, Singh P, Lopez-Jimenez F. Normal Weight Central Obesity: Implications for 
Total and Cardiovascular Mortality Annals of internal medicine. 2015; 163:827–835. [PubMed: 
26551006] 
9Coutinho T, Goel K, Correa de Sa D, Kragelund C, Kanaya AM, Zeller M, Park JS, Kober L, Torp-
Pedersen C, Cottin Y, Lorgis L, Lee SH, Kim YJ, Thomas R, Roger VL, Somers VK, Lopez-
Jimenez F. Central obesity and survival in subjects with coronary artery disease: a systematic review 
of the literature and collaborative analysis with individual subject data J Am Coll Cardiol. 2011; 
57:1877–1886. [PubMed: 21545944] 
10Li C, Engstrom G, Hedblad B, Calling S, Berglund G, Janzon L. Sex differences in the relationships 
between BMI, WHR and incidence of cardiovascular disease: a population-based cohort study Int 
J Obes (Lond). 2006; 30:1775–1781. [PubMed: 16607382] 
11Okorodudu DO, Jumean MF, Montori VM, Romero-Corral A, Somers VK, Erwin PJ, Lopez-
Jimenez F. Diagnostic performance of body mass index to identify obesity as defined by body 
adiposity: a systematic review and meta-analysis Int J Obes (Lond). 2010; 34:791–799. [PubMed: 
20125098] 
12Tice JA, Kanaya A, Hue T, Rubin S, Buist DS, Lacroix A, Lacey JV Jr., Cauley JA, Litwack S, 
Brinton LA, Bauer DC. Risk factors for mortality in middle-aged women Arch Intern Med. 2006; 
166:2469–2477. [PubMed: 17159012] 
13Cerhan JR, Moore SC, Jacobs EJ, Kitahara CM, Rosenberg PS, Adami HO, Ebbert JO, English DR, 
Gapstur SM, Giles GG, Horn-Ross PL, Park Y, Patel AV, Robien K, Weiderpass E, Willett WC, 
Wolk A, Zeleniuch-Jacquotte A, Hartge P, Bernstein L, Berrington de Gonzalez A. A pooled 
analysis of waist circumference and mortality in 650,000 adults Mayo Clinic proceedings. 2014; 
89:335–345. [PubMed: 24582192] 
14LassaleC, TzoulakiI, MoonsKGM, SweetingM, BoerJ, JohnsonL, HuertaJM, AgnoliC, FreislingH, 
WeiderpassE, WennbergP, van derAD, ArriolaL, BenetouV, BoeingH, BonnetF, Colorado-
YoharSM, EngstromG, EriksenAK, FerrariP, GrioniS, JohanssonM, KaaksR, KatsoulisM, 
KatzkeV, KeyTJ, MatulloG, MelanderO, Molina-PortilloE, Moreno-IribasC, NorbergM, 
OvervadK, PanicoS, QuirosJR, SaievaC, SkeieG, SteffenA, StepienM, TjonnelandA, 
TrichopoulouA, TuminoR, van der SchouwYT, VerschurenWMM, LangenbergC, Di 
AngelantonioE, RiboliE, WarehamNJ, DaneshJ, ButterworthAS. Separate and combined 
associations of obesity and metabolic health with coronary heart disease: a pan-European case-
cohort analysis. European heart journal 2017.
Medina-lnojosa et al. Page 8
Am J Cardiol. Author manuscript; available in PMC 2019 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
15Sharma S, Batsis JA, Coutinho T, Somers VK, Hodge DO, Carter RE, Sochor O, Kragelund C, 
Kanaya AM, Zeller M, Park JS, Kober L, Torp-Pedersen C, Lopez-Jimenez F. Normal-Weight 
Central Obesity and Mortality Risk in Older Adults With Coronary Artery Disease Mayo Clinic 
proceedings. 2016; 91:343–351. [PubMed: 26860580] 
16Batsis JA, Sahakyan KR, Rodriguez-Escudero JP, Bartels SJ, Somers VK, Lopez-Jimenez F. Normal 
weight obesity and mortality in United States subjects >/=60 years of age (from the Third National 
Health and Nutrition Examination Survey) Am J Cardiol. 2013; 112:1592–1598. [PubMed: 
23993123] 
17Kvist H, Sjostrom L, Tylen U. Adipose tissue volume determinations in women by computed 
tomography: technical considerations Int J Obes. 1986; 10:53–67. [PubMed: 3710689] 
18Lee HW, Hong TJ, Hong JY, Choi JH, Kim BW, Ahn J, Park JS, Oh JH, Choi JH, Lee HC, Cha KS. 
Waist-hip ratio and 1-year clinical outcome in patients with non-ST-elevation myocardial 
infarctions Coron Artery Dis. 2016; 27:357–364. [PubMed: 27144667] 
19Shiraki T, Saito D. Sex difference of in-hospital mortality in patients with acute myocardial 
infarction Acta Med Okayama. 2011; 65:307–314. [PubMed: 22037267] 
20Blaak E. Gender differences in fat metabolism Curr Opin Clin Nutr Metab Care. 2001; 4:499–502. 
[PubMed: 11706283] 
21Kvist H, Chowdhury B, Sjostrom L, Tylen U, Cederblad A. Adipose tissue volume determination in 
males by computed tomography and 40K Int J Obes. 1988; 12:249–266. [PubMed: 3391740] 
22Bjorkelund C, Lissner L, Andersson S, Lapidus L, Bengtsson C. Reproductive history in relation to 
relative weight and fat distribution Int J Obes Relat Metab Disord. 1996; 20:213–219. [PubMed: 
8653141] 
23Haffner SM, Katz MS, Dunn JF. Increased upper body and overall adiposity is associated with 
decreased sex hormone binding globulin in postmenopausal women Int J Obes. 1991; 15:471–478. 
[PubMed: 1894424] 
24SuperviaM, Medina-InojosaJR, YeungC, Lopez-JimenezF, SquiresRW, Perez-TerzicCM, BrewerLC, 
LethSE, ThomasRJ. Cardiac Rehabilitation for Women: A Systematic Review of Barriers and 
Solutions. Mayo Clinic proceedings 2017.
25See R, Abdullah SM, McGuire DK, Khera A, Patel MJ, Lindsey JB, Grundy SM, de Lemos JA. The 
association of differing measures of overweight and obesity with prevalent atherosclerosis: the 
Dallas Heart Study J Am Coll Cardiol. 2007; 50:752–759. [PubMed: 17707180] 
26Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome The Lancet. 365:1415–1428.
27Song X, Jousilahti P, Stehouwer CD, Soderberg S, Onat A, Laatikainen T, Yudkin JS, Dankner R, 
Morris R, Tuomilehto J, Qiao Q. Cardiovascular and all-cause mortality in relation to various 
anthropometric measures of obesity in Europeans Nutr Metab Cardiovasc Dis. 2015; 25:295–304. 
[PubMed: 25315666] 
28Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, 
Onen CL, Lisheng L, Tanomsup S, Wangai P Jr., Razak F, Sharma AM, Anand SS. Obesity and 
the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study 
Lancet. 2005; 366:1640–1649. [PubMed: 16271645] 
Medina-lnojosa et al. Page 9
Am J Cardiol. Author manuscript; available in PMC 2019 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Highlights
• Women with CAD attending cardiac rehabilitation with higher WHR had a 
greater long-term risk of major adverse cardiovascular events when compared 
to those with a lower WHR.
• A higher WHR was not associated with major adverse cardiovascular events 
in men.
• BMI was not associated with major cardiovascular events.
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Figure 1A. 
Kaplan-Meier curves indicating the relationship between waist to hip ratio tertiles and major 
adverse cardiovascular events among Women.
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Figure 1B. 
Kaplan-Meier curves indicating the relationship between waist to hip ratio tertiles and major 
adverse cardiovascular events among men.
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Table 1.
Baseline patient characteristics
Variable All
(n= 1529)
Men
(N=1133)
Women
(N=396)
Age (years) 63.20 ±12.5 62.10 ±11.87 66.24 ± 13.58 §
Non-Hispanic white 1472(96.3%) 1090(96.2%) 382(96.5%)
Black or African American 24(1.6%) 16(1.4%) 8(2.0%)
Asian 29(1.9%) 23(2.0%) 7(1.8%)
American Indian or Alaska Native 3(0.2%) 3(0.3%) 0
Native Hawaiian/Pacific Islander 1(0.1%) 1(0.1%) 0
Heart failure 274 (17.9%) 180 (15.9%) 94 (23.7%) §
Ever smokers 901 (58.9%) 716 (63.2%) 185 (46.7%) §
Diabetes mellitus 683 (44.7%) 509 (44.9%) 174 (43.9%)
Hypercholesterolemia 1419 (92.8%) 1059 (93.5%) 360 (90.9%)
Hypertension 894 (58.5%) 636 (56.1%) 258 (65.2%) §
Beta blockers use 1107 (72.4%) 816 (72.0%) 291 (73.5%)
Angiotensin converting enzyme inhibitor use 642 (42.0%) 472 (41.7%) 170 (42.9%)
Calcium channel blockers 166 (10.9%) 110 (9.7%) 56 (14.1%) §
Diuretics 447 (29.2%) 295 (26.0%) 152 (38.4%) §
Waist to hip ratio 0.95 (0.1) 0.98 (0.1) 0.86 (0.1)§
Waist to hip ratio sex-adjusted tertile1
     Low 0.91 (0.05) 0.79 (0.05)
     Middle 0.98 (0.03) 0.86 (0.04)
     High 1.04 (0.06) 0.94 (0.07)
Central obesity 1229 (80.4%) 1003 (88.5%) 226 (57.1%) §
Body mass index (Kg/m2) 29.7 ±5.7 29.9 ±5.5 28.9 ±6.2
Values are mean ± standard deviation SD or n (%), unless otherwise indicated.
§
Denotes statistical significance <0.05, compares males vs females.
**
Median and (Interquartile range)
1Waist to hip ratio sex-adjusted tertiles (male Low Tertile: <0.94, Middle Tertile: 0.94 to <1.01, High Tertile: ≥1.01; women Low Tertile : <0.83, 
Middle Tertile: 0.83 to <0.89, High Tertile: ≥0.89).
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Table 2.
Major adverse Cardiovascular Events by Gender
Overall
N=1529
Men
N=1133
Women
N=396
# Major Adverse Cardiovascular Events per Total person years 584/9586 430/7333 154/2253
Major adverse cardiovascular events 415 (27.1%) 307 (27.1%) 108 (27.3%)
Total years of follow up (median) 5.7 (3.58.4) 5.9 (3.8–9.2) 4.9 (3.2–7.7)
Percutaneous Coronary Intervention 133 (32.0%) 101 (32.9%) 32 (29.6%)
Death 107 (25.8%) 77 (25.0%) 30 (27.8%)
Myocardial Infarction 58 (14.0%) 39 (12.7%) 19 (17.6%)
Stroke 42(10.0%) 27 (8.8%) 15 (14.0%)
Coronary Artery Bypass Graft 34 (8.3%) 33(10.8%) 1 (0.9%)
Angina 33 (8.1%) 24 (7.8%) 9 (8.3%)
Ventricular Arrhythmia 8 (1.8%) 6 (2.0%) 2 (1.8%)
Values presented are frequencies and percentages.
Outcomes ascertained electronically: Myocardial infarction ICD-9,410. X; Unstable Angina ICD-9,411.X; Percutaneous Coronary Intervention 
CPT/ ICD-9, 92980– 92982/V45.82; Coronary Artery Bypass Graft CPT/ ICD-9 337700–337735/V45.81; Ventricular arrhythmias ICD-9,427.X; 
Stroke ICD-9, 433.X
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